Damora Therapeutics, Inc.
Ownership
Ownership Structure
Who owns Damora Therapeutics, Inc. (DMRA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 67.1% of the shares are freely tradable; institutional investors hold 102.3%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.65 | 9,045,481 | +3,686.7 | 03/31/2026 |
| Fairmount Funds Management LLC | 14.11 | 8,713,000 | +0.0 | 03/31/2026 |
| venBio Select Advisor LLC | 6.13 | 3,783,000 | +0.0 | 03/31/2026 |
| VR Adviser, LLC | 5.84 | 3,603,595 | +0.0 | 03/31/2026 |
| FCPM III SERVICES BV | 3.95 | 2,441,000 | +0.0 | 03/31/2026 |
| RA Capital Management, LLC | 3.89 | 2,399,310 | +0.0 | 03/31/2026 |
| HHG PLC | 3.83 | 2,362,696 | +135,765.2 | 03/31/2026 |
| Viking Global Investors LP | 3.74 | 2,311,082 | +0.0 | 03/31/2026 |
| Bellevue Group AG | 3.72 | 2,298,000 | +0.0 | 03/31/2026 |
| Remedium Capital Partners, LLC | 3.31 | 2,045,473 | +0.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Jarrett Jennifer | Director, President and CEO | 512,500 | 10,608,750 $ | Sep 25, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Jarrett Jennifer | Director, President and CEO | Buy | 12,500 | 20.23 | 252,875 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.